Branches
National Cancer Centre Singapore
Mon—Fri: 8:30 AM — 5:30 PM
Sat: 8:30 AM — 12:30 PM
Closed on Sunday and Public Holidays
Ongoing trials at National Cancer Centre Singapore
69 trials shown
A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations
This study will assess the safety and efficacy of Osimertinib with Amivantamab as First-line Treatment in Participants with Epidermal Growth Factor Receptor Mutation-Positive, Loca
- Study number:
- NCT05801029
- Cohorts:
- 1
- Study phase:
- 2
- Overall status:
- Not yet recruiting
- Study type:
- Targeted therapy
A Study of EBC-129 in Advanced Solid Tumours
This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours
- Study number:
- NCT05701527
- Cohorts:
- 1
- Study phase:
- 1
- Overall status:
- Recruiting
- Study type:
- Any
A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
To characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of QEQ278 in adult patients with advanced/metastatic non-small cell lu
- Study number:
- NCT05462873
- Cohorts:
- 1
- Study phase:
- 1
- Overall status:
- Recruiting
- Study type:
- Any
Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the 7th most common cancer worldwide but is the 4th deadliest, because diagnosis tend to be late and current systemic therapies are poorly efficac
- Study number:
- NCT05516628
- Cohorts:
- 1
- Study phase:
- 2
- Overall status:
- Not yet recruiting
- Study type:
- Local/Regional therapies, Immunotherapy
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is st
- Study number:
- NCT05635708
- Cohorts:
- 2
- Study phase:
- 2
- Overall status:
- Recruiting
- Study type:
- Any
Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole
This is a phase II study testing the combination of pembrolizumab with lenvatinib, a multi-kinase inhibitor that has activity against vascular endothelial growth factor receptors 1
- Study number:
- NCT05286437
- Cohorts:
- 1
- Study phase:
- 2
- Overall status:
- Recruiting
- Study type:
- Targeted therapy, Hormonal therapy
Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in
This study is the first phase II study of 177Lu-DOTA0-Tyr3-Octreotate in metastatic NPC. Patients whom have failed 2 or more lines of therapy or exhausted standard therapy and are
- Study number:
- NCT05198479
- Cohorts:
- 1
- Study phase:
- 2
- Overall status:
- Not yet recruiting
- Study type:
- Any
Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients
This is a multi-national, phase II, parallel-arm, double-blind, placebo-controlled, two-arm study designed to assess the efficacy and safety of SIRT-Y90 followed by atezolizumab pl
- Study number:
- NCT05377034
- Cohorts:
- 1
- Study phase:
- 2
- Overall status:
- Not yet recruiting
- Study type:
- Local/Regional therapies, Immunotherapy, Targeted therapy
A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma
This Phase 1/ 2 study is a multicenter study to evaluate the safety, tolerability and efficacy of SCG101 in subjects with hepatitis B virus-related hepatocellular carcinoma
- Study number:
- NCT05417932
- Cohorts:
- 1
- Study phase:
- 1, 2
- Overall status:
- Recruiting
- Study type:
- Immunotherapy
Novartis
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
This is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.
- Study number:
- NCT05358249
- Cohorts:
- 3
- Study phase:
- 1, 2
- Overall status:
- Recruiting
- Study type:
- Targeted therapy, Biomarker